Keywords: Novartis, Lucentis, DME, Diabtic macular edema, UK, NICE

Novartis appeals UK NICE negative decision on Lucentis in DME

Article | 03 August 2011

Print This

The UK subsidiary of Swiss drug major Novartis (NOVN: VX) has lodged an appeal against the decision last month by ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in